Hassan Nourmohammadi, Ali Hasanpour Dehkordi, Amir Adibi, Seyed Mohammad Amin Hashemipour, Mohsen Abdan, Moloud Fakhri, Zahra Abdan, Diana Sarokhani
{"title":"献血者中COVID-19血清阳性率:系统回顾和荟萃分析","authors":"Hassan Nourmohammadi, Ali Hasanpour Dehkordi, Amir Adibi, Seyed Mohammad Amin Hashemipour, Mohsen Abdan, Moloud Fakhri, Zahra Abdan, Diana Sarokhani","doi":"10.1155/2022/9342680","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Determining the prevalence of SARS-CoV-2 in blood donors makes the control of virus circulation possible in healthy people and helps implement strategies to reduce virus transmission. The purpose of the study was to examine the seroprevalence of COVID-19 in blood donors using systematic review and meta-analysis.</p><p><strong>Materials and methods: </strong>The electronic databases PubMed, Scopus, Web of Science, and the Google Scholar search engine were searched using standard keywords up to 2022-04-26. The variance of each study was calculated according to the binomial distribution. Studies were combined according to the sample size and variance. <i>Q</i> Cochrane test and I2 index were used to examine the heterogeneity of the studies. Data analysis was performed in STATA 14 software, and the significance level of the tests was <i>P</i> < 0.05.</p><p><strong>Results: </strong>In the 28 papers examined with 227894 samples, the seroprevalence of COVID-19 in blood donors was 10% (95% CI: 9%, 11%), estimated 5% (95% CI: 4%, 7%) among men and 6% (95% CI: 4%, 7%) among women. This rate in different blood groups was as follows: A 12% (95% CI: 10%-14%), B 12% (95% CI: 10%-15%), AB 9% (95% CI: 7%-12%), and O 13% (95% CI: 11%-16%). The seroprevalence of COVID-19 in blood donors in North America 10%, Europe 7%, Asia 23%, South America 5%, and Africa was 4%; Moreover, the seroprevalence of IgG antibodies was estimated to be 23% (95% CI: 18%-29%) and IgM 29% (95% CI: 9%-49%).</p><p><strong>Conclusion: </strong>The highest prevalence of COVID-19 serum in women blood donors was among blood group O and Asia. The seroprevalence of IgG and IgM antibodies was high too.</p>","PeriodicalId":7473,"journal":{"name":"Advances in Virology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334089/pdf/","citationCount":"1","resultStr":"{\"title\":\"Seroprevalence of COVID-19 in Blood Donors: A Systematic Review and Meta-Analysis.\",\"authors\":\"Hassan Nourmohammadi, Ali Hasanpour Dehkordi, Amir Adibi, Seyed Mohammad Amin Hashemipour, Mohsen Abdan, Moloud Fakhri, Zahra Abdan, Diana Sarokhani\",\"doi\":\"10.1155/2022/9342680\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Determining the prevalence of SARS-CoV-2 in blood donors makes the control of virus circulation possible in healthy people and helps implement strategies to reduce virus transmission. The purpose of the study was to examine the seroprevalence of COVID-19 in blood donors using systematic review and meta-analysis.</p><p><strong>Materials and methods: </strong>The electronic databases PubMed, Scopus, Web of Science, and the Google Scholar search engine were searched using standard keywords up to 2022-04-26. The variance of each study was calculated according to the binomial distribution. Studies were combined according to the sample size and variance. <i>Q</i> Cochrane test and I2 index were used to examine the heterogeneity of the studies. Data analysis was performed in STATA 14 software, and the significance level of the tests was <i>P</i> < 0.05.</p><p><strong>Results: </strong>In the 28 papers examined with 227894 samples, the seroprevalence of COVID-19 in blood donors was 10% (95% CI: 9%, 11%), estimated 5% (95% CI: 4%, 7%) among men and 6% (95% CI: 4%, 7%) among women. This rate in different blood groups was as follows: A 12% (95% CI: 10%-14%), B 12% (95% CI: 10%-15%), AB 9% (95% CI: 7%-12%), and O 13% (95% CI: 11%-16%). The seroprevalence of COVID-19 in blood donors in North America 10%, Europe 7%, Asia 23%, South America 5%, and Africa was 4%; Moreover, the seroprevalence of IgG antibodies was estimated to be 23% (95% CI: 18%-29%) and IgM 29% (95% CI: 9%-49%).</p><p><strong>Conclusion: </strong>The highest prevalence of COVID-19 serum in women blood donors was among blood group O and Asia. The seroprevalence of IgG and IgM antibodies was high too.</p>\",\"PeriodicalId\":7473,\"journal\":{\"name\":\"Advances in Virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2022-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334089/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Virology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2022/9342680\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Virology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/9342680","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 1
摘要
引言：确定献血者中严重急性呼吸系统综合征冠状病毒2型的流行率，可以控制健康人的病毒循环，并有助于实施减少病毒传播的策略。本研究的目的是使用系统综述和元分析来检查新冠肺炎在献血者中的血清流行率。材料和方法：使用标准关键词搜索电子数据库PubMed、Scopus、Web of Science和Google Scholar搜索引擎，搜索时间至2022-04-26年。根据二项式分布计算每项研究的方差。根据样本量和方差组合研究。Q Cochrane检验和I2指数用于检验研究的异质性。在STATA 14软件中进行数据分析，检测的显著性水平为P＜0.05。结果：在使用227894份样本检查的28篇论文中，新冠肺炎在献血者中的血清流行率为10%（95%CI:9%，11%），估计男性为5%（95%CI:4%，7%），女性为6%（95%CI4:4%，7%）。不同血型的这一比率如下：A 12%（95%可信区间：10%-14%），B 12%（95%置信区间：10%-15%），AB 9%（95%置信度：7%-12%）和O 13%（95%置信指数：11%-16%）。新冠肺炎在北美献血者中的血清流行率为10%，欧洲为7%，亚洲为23%，南美为5%，非洲为4%；此外，IgG抗体的血清流行率估计为23%（95%CI:18%-29%）和IgM29%（95%CI:9%-49%）。IgG和IgM抗体的血清阳性率也较高。
Seroprevalence of COVID-19 in Blood Donors: A Systematic Review and Meta-Analysis.
Introduction: Determining the prevalence of SARS-CoV-2 in blood donors makes the control of virus circulation possible in healthy people and helps implement strategies to reduce virus transmission. The purpose of the study was to examine the seroprevalence of COVID-19 in blood donors using systematic review and meta-analysis.
Materials and methods: The electronic databases PubMed, Scopus, Web of Science, and the Google Scholar search engine were searched using standard keywords up to 2022-04-26. The variance of each study was calculated according to the binomial distribution. Studies were combined according to the sample size and variance. Q Cochrane test and I2 index were used to examine the heterogeneity of the studies. Data analysis was performed in STATA 14 software, and the significance level of the tests was P < 0.05.
Results: In the 28 papers examined with 227894 samples, the seroprevalence of COVID-19 in blood donors was 10% (95% CI: 9%, 11%), estimated 5% (95% CI: 4%, 7%) among men and 6% (95% CI: 4%, 7%) among women. This rate in different blood groups was as follows: A 12% (95% CI: 10%-14%), B 12% (95% CI: 10%-15%), AB 9% (95% CI: 7%-12%), and O 13% (95% CI: 11%-16%). The seroprevalence of COVID-19 in blood donors in North America 10%, Europe 7%, Asia 23%, South America 5%, and Africa was 4%; Moreover, the seroprevalence of IgG antibodies was estimated to be 23% (95% CI: 18%-29%) and IgM 29% (95% CI: 9%-49%).
Conclusion: The highest prevalence of COVID-19 serum in women blood donors was among blood group O and Asia. The seroprevalence of IgG and IgM antibodies was high too.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
